Winship Cancer Institute Emory University
Welcome,         Profile    Billing    Logout  
 20 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Herrera, Alex
NCT04649112: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Completed
1
13
US
PBCAR19B, Allogeneic Anti-CD19 CAR T cells
Precision BioSciences, Inc.
CD19 Expressing Malignancies, Hematologic Malignancy
12/22
09/23
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
SGN35C-001, NCT06254495: A Safety Study of SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
SGN-35C
Seagen Inc.
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
02/28
08/28
Muffly, Lori
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
10/25
11/26
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
JSP-CP-003, NCT04429191: JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Recruiting
1
40
US
Humanized anti-CD117 Monoclonal Antibody (JSP191), JSP191
Jasper Therapeutics, Inc.
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
10/23
12/23
WUN101-01, NCT05470140: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Active, not recruiting
1
9
US, RoW
WU-NK-101
Wugen, Inc.
Acute Myeloid Leukemia
10/24
01/25
NCT06551584: Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

Not yet recruiting
1
24
US
ORCA-T
Lori Muffly, Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes
05/26
12/26
NCT05507827: Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Recruiting
1
18
US
Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR), Treg CD34+HSPC (Orca-T)
Dr. Melody Smith, MD, MS, Orca Biosystems, Inc.
Lymphoid Leukemia
01/37
01/37
NCT04545333: The clonoSEQ® Watch Registry

Terminated
N/A
465
US
clonoSEQ Assay
Adaptive Biotechnologies
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
10/23
10/23
Kennedy, Vanessa A
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS

Recruiting
1/2
24
Canada, US
VOR33, Mylotarg, gemtuzumab ozogamicin
Vor Biopharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
10/25
01/27

Download Options